Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: Cocaine addiction vulnerability and dopamine transporter function

Neuropsychopharmacology

Volumn 36, Issue 4, 2011, Pages 837-847

  Harvey, Roxann C ^a   Sen, Sucharita ^b   Deaciuc, Agripina ^b   Dwoskin, Linda P ^b   Kantak, Kathleen M ^a  

^a BOSTON UNIVERSITY   (United States)

^b University of Kentucky   (United States)

Author keywords

addiction; attention deficit hyperactivity disorder; cocaine; dopamine transporter function; methylphenidate; spontaneously hypertensive rat

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOSE RESPONSE; DRUG SELF ADMINISTRATION; MALE; MOTIVATION; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REINFORCEMENT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; SUBSTANCE ABUSE; VISUAL DISCRIMINATION; WISTAR KYOTO RAT;

AGE FACTORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ADDICTIVE; COCAINE-RELATED DISORDERS; DISCRIMINATION LEARNING; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; METHYLPHENIDATE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, WISTAR; SPECIES SPECIFICITY;

EID: 79951517905     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.223     Document Type: Article

References (72)

1. Adriani W, Caprioli A, Granstrem O, Carli M, Laviola G (2003). The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopula-tions. Neurosci Biobehav Rev 27: 639-651. (Pubitemid 37414912)
2. Adriani W, Leo D, Greco D, Rea M, di Porzio U, Laviola G et al (2006). Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. Neuropsychopharmacology 31: 1946-1956.
3. American Academy of Pediatrics Committee on Children with Disabilities Committee on Drugs (1996). Medication for children with attentional disorders. Pediatrics 98(2 Pt 1): 301-304.
4. Andersen SL (2003). Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 27: 3-18. (Pubitemid 36535387)
5. Andersen SL, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon WA (2002). Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 5: 13-14. (Pubitemid 34038775)
6. Anker JJ, Perry JL, Gliddon LA, Carroll ME (2009). Impulsivity predicts the escalation of cocaine self-administration in rats. Pharmacol Biochem Behav 93: 343-348.
7. Augustyniak PN, Kourrich S, Rezazadeh SM, Stewart J, Arvanito-giannis A (2006). Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav Brain Res 167: 379-382. (Pubitemid 43099800)
8. Barkley RA, Fischer M, Smallish L, Fletcher K (2003). Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111: 97-109. (Pubitemid 36071038)
9. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B et al (2006). Methylphenidate preferentially increases catecholamine neurotransmission within the prefron-tal cortex at low doses that enhance cognitive function. Biol Psychiatry 60: 1111-1120. (Pubitemid 44647216)
10. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV (1999). Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104: e20.
11. Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T (1998). Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 44: 269-273. (Pubitemid 28389712)
12. Brandon CL, Marinelli M, Baker LK, White FJ (2001). Enhanced reactivity and vulnerability to cocaine following methylpheni-date treatment in adolescent rats. Neuropsychopharmacology 25: 651-661. (Pubitemid 32995947)
13. Carboni E, Tanda GL, Frau R, Di Chiara G (1990). Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55: 1067-1070.
14. Carlezon Jr WA, Mague SD, Andersen SL (2003). Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 54: 1330-1337. (Pubitemid 37522156)
15. Carter LP, Griffiths RR (2009). Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105(Suppl 1): S14-S25.
16. Crofts HS, Dalley JW, Collins P, Van Denderen JC, Everitt BJ, Robbins TW et al (2001). Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cereb Cortex 11: 1015-1026. (Pubitemid 33021232)
17. Da Silva GE, Vendruscolo LF, Takahashi RN (2005). Effects of ethanol on locomotor and anxiety-like behaviors and the acquisition of ethanol intake in Lewis and spontaneously hypertensive rats. Life Sci 77: 693-706. (Pubitemid 40726356)
18. Deroche-Gamonet V, Belin D, Piazza PV (2004). Evidence for addiction-like behavior in the rat. Science 305: 1014-1017. (Pubitemid 39071778)
19. Devilbiss DM, Berridge CW (2008). Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neu-ronal responsiveness. Biol Psychiatry 64: 626-635.
20. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997). Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) 131: 196-206. (Pubitemid 27261609)
21. Ferguson SA, Boctor SY (2010). Cocaine responsiveness or anhedonia in rats treated with methylphenidate during adolescence. Neurotoxicol Teratol 32: 432-442.
22. Finke K, Dodds CM, Bublak P, Regenthal R, Baumann F, Manly T et al. (2010). Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study. Psychopharmacology (Berl) 210: 317-329.
23. Floresco SB, Magyar O, Ghods-Sharifi S, Vexelman C, Tse MT (2006). Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsycho-pharmacology 31: 297-309. (Pubitemid 43113395)
24. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG (1994). Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 269: 15985-15988. (Pubitemid 24209280)
25. Goeders NE, Smith JE (1983). Cortical dopaminergic involvement in cocaine reinforcement. Science 221: 773-775. (Pubitemid 13030639)
26. Goeders NE, Smith JE (1986). Reinforcing properties of cocaine in the medical prefrontal cortex: primary action on presynaptic dopaminergic terminals. Pharmacol Biochem Behav 25: 191-199. (Pubitemid 16040924)
27. Harvey RC, Dembro KA, Rajagopalan K, Mutebi MM, Kantak KM (2009). Effects of self-administered cocaine in adolescent and adult male rats on orbitofrontal cortex-related neurocognitive functioning. Psychopharmacology (Berl) 206: 61-71.
28. Hoffmann O, Plesan A, Wiesenfeld-Hallin Z (1998). Genetic differences in morphine sensitivity, tolerance and withdrawal in rats. Brain Res 806: 232-237. (Pubitemid 29010498)
29. Ikegami A, Duvauchelle CL (2004). Nucleus accumbens and medial prefrontal cortex dopaminergic response to self-administered cocaine in naive rats. Neurosci Lett 354: 205-208. (Pubitemid 38045345)
30. Johansen EB, Sagvolden T (2004). Response disinhibition may be explained as an extinction deficit in an animal model of attention-deficit/hyperactivity disorder (ADHD). Behav Brain Res 149: 183-196. (Pubitemid 38199933)
31. Kantak KM, Black Y, Valencia E, Green-Jordan K, Eichenbaum HB (2002). Dissociable effects of lidocaine inactivation of the rostral and caudal basolateral amygdala on the maintenance and reinstatement of cocaine-seeking behavior in rats. J Neurosci 22: 1126-1136. (Pubitemid 34141792)
32. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS (2000). Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 148: 251-262. (Pubitemid 30136732)
33. Kantak KM, Green-Jordan K, Valencia E, Kremin T, Eichenbaum HB (2001). Cognitive task performance after lidocaine-induced inactivation of different sites within the basolateral amygdala and dorsal striatum. Behav Neurosci 115: 589-601. (Pubitemid 32565663)
34. Kantak KM, Singh T, Kerstetter KA, Dembro KA, Mutebi MM, Harvey RC et al (2008). Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. Behav Neurosci 122: 340-357. (Pubitemid 351672325)
35. Kollins SH (2008). A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 24: 1345-1357. (Pubitemid 351741566)
36. Kuczenski R, Segal DS (2002). Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepi-nephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22: 7264-7271.
37. Lambert NM, Hartsough CS (1998). Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 31: 533-544.
38. Levin FR, Evans SM, Brooks DJ, Garawi F (2007). Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87: 20-29. (Pubitemid 46074379)
39. Mannuzza S, Klein RG, Truong NL, Moulton III JL, Roizen ER, Howell KH et al (2008). Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 165: 604-609. (Pubitemid 351705337)
40. Masana M, Bortolozzi A, Artigas F (2010). Selective enhacement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int J Neu-ropsychopharmacol, print copy in press (originally published online 12 August 2010 at http://www.journals.cambridge. org/).
41. Mehta MA, Goodyer IM, Sahakian BJ (2004). Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 45: 293-305. (Pubitemid 38240276)
42. Mill J, Sagvolden T, Asherson P (2005). Sequence analysis of Drd2, Drd4, and Dat1 in SHR and WKY rat strains. Behav Brain Funct 1: 24.
43. Moll GH, Hause S, Ruther E, Rothenberger A, Huether G (2001). Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 11: 15-24. (Pubitemid 32295179)
44. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002). Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22: 389-395. (Pubitemid 34049076)
45. Mundorf ML, Joseph JD, Austin CM, Caron MG, Wightman RM (2001). Catecholamine release and uptake in the mouse prefrontal cortex. J Neurochem 79: 130-142. (Pubitemid 32946650)
46. Pandolfo P, Pamplona FA, Prediger RD, Takahashi RN (2007). Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55212-2 Eur J Pharmacol 563: 141-148. (Pubitemid 46602239)
47. Pandolfo P, Vendruscolo LF, Sordi R, Takahashi RN (2009). Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder. Psychopharmacology (Berl) 205: 319-326.
48. Piazza PV, Deroche-Gamonent V, Rouge-Pont F, Le Moal M (2000). Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction. J Neurosci 20: 4226-4232. (Pubitemid 30365693)
49. Pum M, Carey RJ, Huston JP, Muller CP (2007). Dissociating effects of cocaine and d-amphetamine on dopamine and serotonin in the perirhinal, entorhinal, and prefrontal cortex of freely moving rats. Psychopharmacology (Berl) 193: 375-390. (Pubitemid 47063512)
50. Ramamoorthy S, Samuvel DJ, Balasubramaniam A, See RE, Jayanthi LD (2010). Altered dopamine transporter function and phosphorylation following chronic cocaine self-administration and extinction in rats. Biochem Biophys Res Commun 391: 1517-1521.
51. Robbins TW (2002). ADHD and addiction. Nat Med 8: 24-25. (Pubitemid 34101719)
52. Roberts DC, Loh EA, Vickers G (1989). Self-administration of cocaine on a progressive ratio schedule in rats: dose-response relationship and effect of haloperidol pretreatment. Psychophar-macology (Berl) 97: 535-538. (Pubitemid 19102558)
53. Roessner V, Sagvolden T, Dasbanerjee T, Middleton FA, Faraone SV, Walaas SI et al (2010). Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/ hyperactivity disorder inattentive type. Neuroscience 167: 1183-1191.
54. Russell VA (2007). Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci Methods 161: 185-198. (Pubitemid 46466956)
55. Sagvolden T, Johansen EB, Woien G, Walaas SI, Storm-Mathisen J, Bergersen LH et al (2009). The spontaneously hypertensive rat model of ADHD-the importance of selecting the appropriate reference strain. Neuropharmacology 57: 619-626.
56. Sagvolden T, Metzger MA, Schiorbeck HK, Rugland AL, Spinnangr I, Sagvolden G (1992). The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomotor stimulants. Behav Neural Biol 58: 103-112.
57. Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M (2005). Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 57: 1239-1247. (Pubitemid 40798541)
58. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N et al (2002). Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 10: 286-294. (Pubitemid 34919937)
59. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI (1998). Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18: 2697-2708. (Pubitemid 28141815)
60. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H et al (2004). Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuro-psychopharmacology 29: 1790-1799. (Pubitemid 39336790)
61. Soeters HS, Howells FM, Russell VA (2008). Methylphenidate does not increase ethanol consumption in a rat model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Metab Brain Dis 23: 303-314.
62. Szobot CM, Rohde LA, Katz B, Ruaro P, Schaefer T, Walcher M et al (2008). A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactiv-ity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res 41: 250-257. (Pubitemid 351761080)
63. Thanos PK, Michaelides M, Benveniste H, Wang GJ, Volkow ND (2007). Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol Biochem Behav 87: 426-433. (Pubitemid 47248631)
64. Thanos PK, Ivanov I, Robinson JK, Michaelides M, Wang GJ, Swanson JM et al. Dissociation between spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats in baseline performance and methylphenidate response on measures of attention|, impulsivity and hyperactivity in a Visual Stimulus Position Discrimination Task. Pharmacol Biochem Behav (2010) 94: 374-379.
65. Vadum A, Rankin NM (1998). Psychological Research: Methods for Discovery and Validation. McGraw-Hill: New York.
66. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV et al (2007). Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 34: 1182-1190. (Pubitemid 46394475)
67. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL et al (1998). Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 63: 1767-1776. (Pubitemid 30415740)
68. Wells AM, Janes AC, Liu X, Deschepper CF, Kaufman MJ, Kantak KM (2010). Medial temporal lobe functioning and structure in the spontaneously hypertensive rat: comparison with Wistar-Kyoto normotensive and Wistar-Kyoto hypertensive strains. Hippocampus 20: 787-797.
69. Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111: 179-185. (Pubitemid 36071051)
70. Winer BJ, Brown BD, Michels KM (1991). Statistical Principles in Experimental Design, 3rd edn. McGraw-Hill: New York.
71. Zhu J, Apparsundaram S, Dwoskin LP (2009). Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. J Pharmacol Exp Ther 328: 931-939.
72. Zhu J, Green T, Bardo MT, Dwoskin LP (2004). Environmental enrichment enhances sensitization to GBR 12935-induced activity and decreases dopamine transporter function in the medial prefrontal cortex. Behav Brain Res 148: 107-117. (Pubitemid 37543660)